Resverlogix Corp. has announced today that it has made significant advancement in the Company's research and development (R&D) program for inflammatory diseases.
Two new patent applications have been filed for novel compounds and their use in regulating inflammatory markers. Inflammatory markers are proteins generated by the body during periods of inflammation. These patents were filed based on the successful results demonstrated in numerous preclinical studies across several disease areas. The particular results achieved in the collagen induced arthritis (CIA) model in rats demonstrated that Resverlogix's proprietary molecules markedly reduced inflammation while improving mobility of arthritic animals.
"Resverlogix's R&D program has made significant strides this past year," said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has identified several molecules that have the potential for disease modifying effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's R&D team is continuing to examine the various disease indications in inflammation which would have the greatest potential impact for both patients and payer groups," continued McCaffrey.
A significant unmet medical need exists for safe, effective and economical therapies for specific inflammation markets. For example, a small molecular drug for rheumatoid arthritis is estimated to range in price from US $180 - US $6000 per person per annum. A biologic, or large molecule drug, can cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007, the global market for rheumatoid arthritis alone was estimated to be in excess of US $11 billion a year and is expected to grow to US $27 billion by the year 2015. These important markets require novel therapies to reduce pain and symptoms in a cost efficient manner. Resverlogix's novel small molecules have the illustrated early potential to fill this important gap.